DEPO-MEDROL 20 MG
METHYLPREDNISOLONE ACETATE : 20 MG · DIN 01934325 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is DEPO-MEDROL?
DEPO-MEDROL 20 MG contains METHYLPREDNISOLONE ACETATE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 01934325, held by PFIZER CANADA ULC, supplied as SUSPENSION for INTRASYNOVIAL ; INTRA-ARTICULAR ; INTRAMUSCULAR ; INTRALESIONAL administration. Health Canada currently lists it as marketed, status dated 03-May-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DEPO-MEDROL used for?
Endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, GI, respiratory, hematologic, and neoplastic diseases. Used IM, intra-articularly, intrasynovially, or intralesionally.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01934325 |
|---|---|
| Brand name | DEPO-MEDROL |
| Generic / active ingredient | METHYLPREDNISOLONE ACETATE : 20 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 20 MG |
| Dosage form | SUSPENSION |
| Route of administration | INTRASYNOVIAL ; INTRA-ARTICULAR ; INTRAMUSCULAR ; INTRALESIONAL |
| Schedule | Prescription |
| ATC code | H02AB04 METHYLPREDNISOLONE |
| AHFS class | 68:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-May-2006 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Dosage varies by condition and route. Intra-articular: 4-80 mg based on joint size. IM: 40-120 mg. Intralesional: 20-60 mg. Must be individualized and decreased gradually.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard practice is 15-30°C, but section 11 was not fully included).
How is it supplied?
Benzyl alcohol formula: 20 mg/mL (5 mL), 40 mg/mL (2 & 5 mL), 80 mg/mL (5 mL). MGPC formula: 40 mg/mL (1 mL), 80 mg/mL (1 mL).
Contraindications
Hypersensitivity; systemic fungal infections; IM use in idiopathic thrombocytopenic purpura; live vaccines; herpes simplex of the eye; vaccinia/varicella; epidural/intrathecal/intravascular use.
Warnings and precautions
Risk of HPA axis suppression; serious events with unauthorized routes; potential toxicity of benzyl alcohol to neural tissue; risk of Kaposi’s sarcoma; caution in CHF and hypertension.
What can be used instead?
Other Canadian products sharing ATC code H02AB04 METHYLPREDNISOLONE. 13 of 34 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DEPO-MEDROL | 40 MG | SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 00030759 |
| DEPO-MEDROL | 40 MG | SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 01934333 |
| DEPO-MEDROL | 80 MG | SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 01934341 |
| DEPO-MEDROL | 80 MG | SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 00030767 |
| MEDROL | 16 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 00036129 |
| MEDROL | 4 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 00030988 |
| SOLU-MEDROL | 1 G | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00036137 |
| SOLU-MEDROL | 1 G | KIT ; POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02367971 |
| SOLU-MEDROL | 125 MG | POWDER FOR SOLUTION ; KIT | PFIZER CANADA ULC | MARKETED | DIN 02367955 |
| SOLU-MEDROL | 40 MG | KIT ; POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02367947 |
Who else supplies METHYLPREDNISOLONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHYLPREDNISOLONE appears in 18 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.